Optics - Zeiss Meditec reaches two billion mark in sales
The Thuringian medical technology group Carl Zeiss Meditec reached the two billion euro revenue mark for the first time in the past financial year. High demand for lasers, intraocular lenses and surgical microscopes for the treatment of eye diseases following the coronavirus pandemic led to an increase in revenue of around ten percent to just under EUR 2.1 billion. This was announced by the Management Board on Tuesday when presenting the figures for the 2022/23 financial year. However, earnings before interest and taxes (EBIT) fell from 397 million euros to 348 million euros. Nevertheless, the dividend for shareholders is set to remain at 1.10 euros per share, as in the previous year.
CEO Markus Weber sees the prospects for the new financial year as fundamentally positive, with the long-term development trends continuing despite increased uncertainty. There is still a high demand worldwide for the treatment of widespread diseases such as short-sightedness and cataracts. Despite a somewhat slower pace in China, sales growth for the entire 2023/24 financial year is expected to be at least in line with market growth.
The Group, which is listed on the Frankfurt Stock Exchange's MDax, employs around 4800 people in Germany and abroad, including more than 2200 in Germany. Zeiss Meditec specializes in devices and materials for the treatment of eye diseases.
Read also:
- A clan member is punished here
- Traffic lawyer warns: Don't talk to the police!
- Will he be convicted as Jutta's murderer after 37 years?
- He also wanted to kill his cousin
- The significant increase in sales for Optics company Zeiss Meditec in Thuringia during the 2022/23 financial year was largely attributed to the high demand for treatments related to eye diseases, including lasers and intraocular lenses, resulted from the coronavirus pandemic.
- Zeiss Meditec, a German medical technology group based in Thuringia, reported a turnover of around EUR 2.1 billion for the past financial year, marking their first-ever two billion mark in sales, despite a decrease in earnings before interest and taxes (EBIT).
- Even though the Coronavirus pandemic has brought uncertainties for the upcoming financial year, the CEO of Zeiss Meditec, Markus Weber, maintains a positive outlook due to the high demand worldwide for the treatment of widespread eye diseases like short-sightedness and cataracts.
- As a part of Germany's medical technology sector, Zeiss Meditec, which has its presence in both Germany and abroad, focuses on the development and production of devices and materials for the treatment of various eye diseases, contributing to the country's thriving medical technology market.
Source: www.stern.de
